Real world efficacy and safety of teriflunomide in patients with relapsing-remitting multiple sclerosis

dc.contributor.authorBoz, Cavit
dc.contributor.authorÖzakbaş, Serkan
dc.contributor.authorTerzi, Murat
dc.contributor.authorTürkoğlu, Recai
dc.contributor.authorAkman, Gülşen
dc.contributor.authorEfendi, Hüsnü
dc.contributor.authorAkçalı, Aylin
dc.contributor.authorTuncer, Alaettin
dc.contributor.authorYüceyar, Nur
dc.contributor.authorSoysal, Aysun
dc.contributor.authorKöseoğlu, M.
dc.contributor.authorBalcı, Belgin Petek
dc.contributor.authorSevim, Serhan
dc.contributor.authorAltıntaş, Ayşe
dc.contributor.authorÇilingir, Vedat
dc.contributor.authorDemirkıran, Meltem
dc.contributor.authorKızılay, Ferah
dc.contributor.authorAltunrende, Burcu
dc.contributor.buuauthorTuran, Ömer Faruk
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.tr_TR
dc.date.accessioned2023-08-08T13:31:23Z
dc.date.available2023-08-08T13:31:23Z
dc.date.issued2017-10
dc.descriptionBu çalışma, 25-28, Ekim 2017 tarihlerinde Paris[Fransa]’ de düzenlenen 7. Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) Kongresi‘nde bildiri olarak sunulmuştur.tr_TR
dc.description.sponsorshipMerck & Companyen_US
dc.description.sponsorshipNovartisen_US
dc.description.sponsorshipBayer AGen_US
dc.description.sponsorshipTeva Pharmaceutical Industriesen_US
dc.description.sponsorshipEuropean Comm Treatment & Res Multiple Sclerosisen_US
dc.description.sponsorshipAmericas Comm Treatment & Res Multiple Sclerosisen_US
dc.identifier.citationBoz, C. vd. (2017). ''Real world efficacy and safety of teriflunomide in patients with relapsing-remitting multiple sclerosis''. Multiple Sclerosis Journal, 23(Supplement 3), 327-328.en_US
dc.identifier.endpage328tr_TR
dc.identifier.issn1352-4585
dc.identifier.issn1477-0970
dc.identifier.issueSuplement 3en_US
dc.identifier.startpage327tr_TR
dc.identifier.urihttps://journals.sagepub.com/toc/msja/23/3_suppl
dc.identifier.urihttp://hdl.handle.net/11452/33415
dc.identifier.volume23tr_TR
dc.identifier.wos000413730202068tr_TR
dc.indexed.wosSCIEen_US
dc.indexed.wosCPCISen_US
dc.language.isoenen_US
dc.publisherSage Puplicationsen_US
dc.relation.collaborationYurt içitr_TR
dc.relation.collaborationSanayitr_TR
dc.relation.journalMultiple Sclerosis Journalen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararasıtr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNeurosciences & neurologyen_US
dc.subject.wosClinical neurologyen_US
dc.subject.wosNeurosciencesen_US
dc.titleReal world efficacy and safety of teriflunomide in patients with relapsing-remitting multiple sclerosisen_US
dc.typeMeeting Abstract
dc.wos.quartileQ1en_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections